Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Market Perform to Outperform. Analyst Price Forecast Suggests 42 ...

2 days ago · Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals from Market Perform to Outperform.. What is the Fund Sentiment? There are 2,471 funds ...

2 days ago · Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) was upgraded by equities researchers at Leerink Partners from a "market perform" rating to an "outperform" rating in a report issued on Wednesday,Finviz reports. The firm currently has a $834.00 price objective on the biopharmaceutical company's stock, up from their prior price objective ...

Jan 28, 2025 · Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Market Perform to Outperform. As of January 28, 2025, the ...

19 hours ago · According to a CNBC report, Leerink Partners analyst David Risinger upgraded the stock to 'Outperform' on Wednesday and raised his price target to $834 from $762. This implies about 15% upside from current levels. ... Regeneron shares trade nearly 30% below Wall Street's consensus price target of $939.37, according to Koyfin data. ...

1 day ago · Regeneron Pharmaceuticals had a return on equity of 16.88% and a net margin of 33.61%. The firm's revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $11.86 EPS. Sell-side analysts forecast that Regeneron Pharmaceuticals will post 37.75 earnings per share for the current year.

2 days ago · Leerink upgraded Regeneron to Outperform from Market Perform with a price target of $834, up from $762. The shares have fallen 35% over the past six months, creating an opportunity to capitalize ...

2 days ago · Analyst David Risinger upgraded shares to outperform. He also raised his price target to $834 from $762.

2 days ago · Leerink Upgrades Regeneron Pharmaceuticals to Outperform From Market Perform, Adjusts PT to $834 From $762 06:53am: MT TD Cowen Cuts Price Target on Regeneron Pharmaceuticals to $970 From $1,030 Feb. 04: MT

Jan 28, 2025 · Regeneron Pharmaceuticals, Inc. Announces Adjuvant Libtayo Significantly Improves Disease-Free Survival After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma in Phase 3 Trial Jan. 13 CI